Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 earnings results
Ironwood Pharmaceuticals, Inc. (IRWD) reported Q3 2026 results on Nov 5, 2026, 7:05:38 AM ET: adjusted EPS $0.36 vs. $0.31 expected (beat by 16.1%); revenue $133.04M vs. $121.57M expected (beat by 9.4%). Outlook: Raises full-year 2026 total revenue guidance to $485 - $510 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $0.36 | $0.31 | Beat by 16.1% |
| Revenue | $133.04M | $121.57M | Beat by 9.4% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 7:05:38 AM ET. Nexqual published them 2 min 47 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 9.0% from $122.06M.
Stock reaction
The results came out before the market opened. IRWD closed at $4.03 on November 5, 2026, up 6.9% from its $3.77 close on November 4, 2026 before the results. Latest: $4.84 as of 11:45 AM ET, +28.5% since the pre-release close.
Questions and answers
Did Ironwood Pharmaceuticals, Inc. beat earnings expectations?
Yes. Ironwood Pharmaceuticals, Inc. reported adjusted EPS of $0.36 against an average analyst estimate of $0.31 (beat by 16.1%), and revenue of $133.04M against $121.57M expected (beat by 9.4%).
What were Ironwood Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $0.36 and revenue of $133.04M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 9.0% from $122.06M.
When did Ironwood Pharmaceuticals, Inc. report Q3 2026 earnings?
Nov 5, 2026, 7:05:38 AM ET, in an SEC 8-K filing (Item 2.02).
How did IRWD stock react to the earnings?
The results came out before the market opened. IRWD closed at $4.03 on November 5, 2026, up 6.9% from its $3.77 close on November 4, 2026 before the results. Latest: $4.84 as of 11:45 AM ET, +28.5% since the pre-release close.
What did Ironwood Pharmaceuticals, Inc. say about its outlook?
Raises full-year 2026 total revenue guidance to $485 - $510 million.
More on IRWD
IRWD stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:45 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:45 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt